WAVE LIFE SCIENCES LTD. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
WAVE LIFE SCIENCES LTD. (WVE) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$8.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $5.20M, a 0.27% decline year-over-year.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$13.52M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $10.08M, a 45.22% increase year-over-year.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $3.46M, a 0.12% decline year-over-year.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $5.48M, a 28.92% increase from fiscal 2024.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $4.25M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$724.00K, a 126.90% decline from fiscal 2022.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $2.69M, a 6.89% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$8.32M 10-Q · filed 2026-07-30 | $1.75M derived: sum of 3 quarters · filed 2026-07-30 | $5.22M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$13.52M 10-Q · filed 2026-04-28 | -$3.44M derived: sum of 2 quarters · filed 2026-04-28 | $17.00K derived: sum of 3 quarters · filed 2026-04-28 | $5.23M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $10.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.54M derived: sum of 2 quarters · filed 2026-02-26 | $18.75M derived: sum of 3 quarters · filed 2026-07-30 | $5.48M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $8.67M derived: sum of 2 quarters · filed 2026-07-30 | -$4.59M 10-Q · filed 2025-11-10 | $2.35M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $5.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$8.05M 10-Q · filed 2026-07-30 | -$1.12M derived: sum of 3 quarters · filed 2026-07-30 | $2.35M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$13.27M 10-Q · filed 2026-04-28 | -$6.33M derived: sum of 2 quarters · filed 2026-04-28 | -$2.86M derived: sum of 3 quarters · filed 2026-04-28 | $1.19M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $6.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.40M derived: sum of 2 quarters · filed 2026-02-26 | $14.46M derived: sum of 3 quarters · filed 2026-02-26 | $4.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $7.52M derived: sum of 2 quarters · filed 2025-11-10 | -$2.69M 10-Q · filed 2025-11-10 | $1.52M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$6.15M 10-Q · filed 2025-07-30 | -$1.95M derived: sum of 3 quarters · filed 2026-02-26 | $248.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$10.21M 10-Q · filed 2025-05-08 | -$6.00M derived: sum of 2 quarters · filed 2026-02-26 | -$3.81M derived: sum of 3 quarters · filed 2026-02-26 | -$1.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.40M derived: sum of 2 quarters · filed 2026-02-26 | $9.21M derived: sum of 3 quarters · filed 2026-02-26 | -$724.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.00M derived: sum of 2 quarters · filed 2024-11-12 | -$4.93M 10-Q · filed 2024-11-12 | $1.57M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$7.12M 10-Q · filed 2024-08-08 | -$627.00K derived: sum of 3 quarters · filed 2025-03-04 | -$656.00K derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | -$9.93M 10-Q · filed 2024-05-10 | -$3.43M derived: sum of 2 quarters · filed 2025-03-04 | -$3.46M derived: sum of 3 quarters · filed 2025-03-04 | $693.00K derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $6.47M derived: sum of 2 quarters · filed 2025-03-04 | $10.62M derived: sum of 3 quarters · filed 2025-03-04 | $2.69M 10-K · filed 2025-03-04 |
| 2022-09-30 | -$29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.13M derived: sum of 2 quarters · filed 2023-11-09 | -$3.81M 10-Q · filed 2023-11-09 | -$308.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $4.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$3.78M 10-Q · filed 2023-08-03 | -$279.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.16M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$7.93M 10-Q · filed 2023-05-03 | -$4.43M derived: sum of 2 quarters · filed 2023-05-03 | -$2.99M derived: sum of 3 quarters · filed 2023-05-03 | $268.00K derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $4.94M derived: sum of 2 quarters · filed 2023-03-23 | $8.20M derived: sum of 3 quarters · filed 2023-03-23 | $2.89M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $4.70M derived: sum of 2 quarters · filed 2022-11-10 | -$607.00K 10-Q · filed 2022-11-10 | $1.18M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $3.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$2.05M 10-Q · filed 2022-08-11 | -$259.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.70M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$5.31M 10-Q · filed 2022-05-12 | -$3.52M derived: sum of 2 quarters · filed 2022-05-12 | -$1.56M derived: sum of 3 quarters · filed 2022-05-12 | -$4.33M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $3.75M derived: sum of 2 quarters · filed 2022-03-03 | $977.00K derived: sum of 3 quarters · filed 2022-03-03 | -$4.21M 10-K · filed 2022-03-03 |
| 2020-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$812.00K derived: sum of 2 quarters · filed 2021-11-10 | -$6.00M 10-Q · filed 2021-11-10 | -$3.56M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$7.96M 10-Q · filed 2021-08-05 | -$5.52M derived: sum of 3 quarters · filed 2021-08-05 | -$3.41M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$5.19M 10-Q · filed 2021-05-13 | -$2.75M derived: sum of 2 quarters · filed 2021-05-13 | -$639.00K derived: sum of 3 quarters · filed 2021-05-13 | $2.72M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $4.55M derived: sum of 2 quarters · filed 2021-03-04 | $7.92M derived: sum of 3 quarters · filed 2021-03-04 | $1.45M 10-K · filed 2021-03-04 |
| 2019-09-30 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $5.47M derived: sum of 2 quarters · filed 2020-11-09 | -$998.00K 10-Q · filed 2020-11-09 | $4.22M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$3.10M 10-Q · filed 2020-08-10 | $2.11M derived: sum of 3 quarters · filed 2020-08-10 | |
| 2019-03-31 | -$6.47M 10-Q · filed 2020-05-11 | -$1.25M derived: sum of 2 quarters · filed 2020-05-11 | ||
| 2018-12-31 | $5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $5.86M 10-K · filed 2020-03-02 | ||
| 2018-09-30 | $647.00K 10-Q · filed 2019-11-05 | |||
| 2017-12-31 | $4.55M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |